Revenio Group Corporation: CORRECTION TO WEEKDAY MENTIONED IN THE NOTICE OF ANNUAL GENERAL MEETING PUBLISHED ON 22 FEBRUARY, 2018

Revenio Group Corporation, Stock Exchange Release, 22 February 2018 at 15:00          
                     
CORRECTION TO WEEKDAY MENTIONED IN THE NOTICE OF ANNUAL GENERAL MEETING PUBLISHED ON 22 FEBRUARY, 2018

In the Notice of Annual General Meeting that was published today on 22 February 2018 at 12.00 EET is incorrectly stated the weekday to be Wednesday. The Annual General Meeting will be held on Tuesday 20 March 2018 at 4.30 p.m.

REVENIO GROUP CORPORATION

For further information, please contact:
CEO and President Timo Hildén
tel. +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi

Attachment: Notice of General Meeting

DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2017, Revenio Group's net sales totaled EUR 26.8 million, with its operating margin, excluding non-recurring items, standing at 35.5 %. Revenio Group Corporation is listed on Nasdaq Helsinki.